Literature DB >> 10452565

The role of antimicrobial therapy in acute exacerbations of chronic bronchitis.

G D Campbell1.   

Abstract

Acute exacerbations of chronic bronchitis (AECB) result in increased morbidity and mortality. The role of bacteria in AECB, the importance of antimicrobial therapy, and the choice of antimicrobial agents have been debated for decades. Fortunately, within the past few years, a number of studies and one consensus statement have been reported that have increased the understanding of the role of bacteria in AECB and suggest approaches in selecting antimicrobial therapy. This article will review these studies and present an empiric approach in treating AECB based upon the patient's presenting findings, related risk factors, and potential antimicrobial resistance patterns that may be encountered.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10452565     DOI: 10.1097/00000441-199908000-00004

Source DB:  PubMed          Journal:  Am J Med Sci        ISSN: 0002-9629            Impact factor:   2.378


  4 in total

1.  Efficacy and safety of pharmacokinetically enhanced amoxicillin-clavulanate at 2,000/125 milligrams twice daily for 5 days versus amoxicillin-clavulanate at 875/125 milligrams twice daily for 7 days in the treatment of acute exacerbations of chronic bronchitis.

Authors:  Sanjay Sethi; John Breton; Brian Wynne
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

Review 2.  Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections.

Authors:  J A Balfour; H M Lamb
Journal:  Drugs       Date:  2000-01       Impact factor: 9.546

Review 3.  Levofloxacin: a review of its use in the treatment of bacterial infections in the United States.

Authors:  Katherine F Croom; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 4.  Levofloxacin: an updated review of its use in the treatment of bacterial infections.

Authors:  Miriam Hurst; Harriet M Lamb; Lesley J Scott; David P Figgitt
Journal:  Drugs       Date:  2002       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.